$ANVS
Annovis Bio, Inc.

2024 Q3 Form 10-Q Financial Statement

#000155837024012227 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.698M $1.977M
YoY Change 64.86% 32.05%
% of Gross Profit
Research & Development $2.690M $5.785M
YoY Change -80.56% -29.98%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $4.388M $7.763M
YoY Change -70.48% -20.46%
Operating Profit -$4.388M -$7.763M
YoY Change -70.48% -20.46%
Interest Expense -$7.727M $25.98K
YoY Change -5368.61% -88.33%
% of Operating Profit
Other Income/Expense, Net -$8.251M $2.742M
YoY Change -5725.96% 1132.03%
Pretax Income -$12.64M -$5.020M
YoY Change -14.12% -47.36%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$12.64M -$5.020M
YoY Change -14.12% -47.36%
Net Earnings / Revenue
Basic Earnings Per Share -$0.97 -$0.44
Diluted Earnings Per Share -$0.97 -$0.44
COMMON SHARES
Basic Shares Outstanding 13.05M 11.17M
Diluted Shares Outstanding 12.98M 11.31M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.64M $3.998M
YoY Change 99.0% -74.58%
Cash & Equivalents $12.60M $4.000M
Short-Term Investments
Other Short-Term Assets $1.725M $1.049M
YoY Change -55.43% -85.21%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $14.36M $5.046M
YoY Change 40.48% -77.88%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets -$4.00 -$5.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $14.36M $5.046M
Total Long-Term Assets -$4.00 -$5.00
Total Assets $14.36M $5.046M
YoY Change 40.48% -77.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.099M $3.395M
YoY Change 112.8% 189.43%
Accrued Expenses $1.292M $662.7K
YoY Change -21.22% -26.45%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.391M $4.057M
YoY Change 51.24% 95.64%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.907M $2.740M
YoY Change
Total Long-Term Liabilities $1.907M $2.740M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.391M $4.057M
Total Long-Term Liabilities $1.907M $2.740M
Total Liabilities $7.298M $6.797M
YoY Change 104.71% 227.76%
SHAREHOLDERS EQUITY
Retained Earnings -$129.0M -$116.3M
YoY Change 46.51% 58.6%
Common Stock $1.328K $1.172K
YoY Change 47.23% 29.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.064M -$1.751M
YoY Change
Total Liabilities & Shareholders Equity $14.36M $5.046M
YoY Change 40.48% -77.88%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$12.64M -$5.020M
YoY Change -14.12% -47.36%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$3.201M -$3.375M
YoY Change -65.83% -64.86%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 11.84M 4.236M
YoY Change -50.58%
NET CHANGE
Cash From Operating Activities -3.201M -3.375M
Cash From Investing Activities
Cash From Financing Activities 11.84M 4.236M
Net Change In Cash 8.639M 860.8K
YoY Change -192.2% -183.24%
FREE CASH FLOW
Cash From Operating Activities -$3.201M -$3.375M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
dei Entity Central Index Key
EntityCentralIndexKey
0001477845
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10519933
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11721480
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39202
dei Entity Registrant Name
EntityRegistrantName
Annovis Bio, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-2540421
dei Entity Address Address Line1
EntityAddressAddressLine1
101 Lindenwood Drive, Suite 225
dei Entity Address City Or Town
EntityAddressCityOrTown
Malvern
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19355
dei City Area Code
CityAreaCode
484
dei Local Phone Number
LocalPhoneNumber
875-3192
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
ANVS
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13054018
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3997767
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5754720
CY2024Q2 anvs Prepaid Expense Security Deposits And Other Assets Current
PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
1048688
CY2023Q4 anvs Prepaid Expense Security Deposits And Other Assets Current
PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
4453544
CY2024Q2 us-gaap Assets
Assets
5046455
CY2023Q4 us-gaap Assets
Assets
10208264
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3394657
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1292837
CY2024Q2 anvs Accrued Liabilities And Interest And Employee Related Liabilities Current
AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
662682
CY2023Q4 anvs Accrued Liabilities And Interest And Employee Related Liabilities Current
AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
2986273
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4057339
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4279110
CY2024Q2 anvs Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
2235000
CY2023Q4 anvs Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
13680000
CY2024Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
505000
CY2024Q2 us-gaap Liabilities
Liabilities
6797339
CY2023Q4 us-gaap Liabilities
Liabilities
17959110
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11721480
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10519933
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
1172
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1052
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
114594390
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
102507189
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116346446
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110259087
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-1750884
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-7750846
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5046455
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10208264
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5785217
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8262167
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12307308
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16048223
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1977421
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1497533
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3265137
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3681193
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
7762638
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
9759700
us-gaap Operating Expenses
OperatingExpenses
15572445
us-gaap Operating Expenses
OperatingExpenses
19729416
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7762638
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9759700
us-gaap Operating Income Loss
OperatingIncomeLoss
-15572445
us-gaap Operating Income Loss
OperatingIncomeLoss
-19729416
CY2024Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
25978
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
222578
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
70146
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
455113
CY2024Q2 anvs Financing Costs From Issuance Of Shares
FinancingCostsFromIssuanceOfShares
1346060
anvs Financing Costs From Issuance Of Shares
FinancingCostsFromIssuanceOfShares
1346060
CY2024Q2 anvs Gain Loss On Changes In Fair Value Of Warrant Liability
GainLossOnChangesInFairValueOfWarrantLiability
4062308
anvs Gain Loss On Changes In Fair Value Of Warrant Liability
GainLossOnChangesInFairValueOfWarrantLiability
10761000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2742226
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
222578
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9485086
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
455113
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5020412
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9537122
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6087359
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19274303
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-5020412
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9537122
us-gaap Net Income Loss
NetIncomeLoss
-6087359
us-gaap Net Income Loss
NetIncomeLoss
-19274303
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.25
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.07
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.52
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.25
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11307759
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8951309
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10966412
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8575239
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11307759
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11307759
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8951309
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8951309
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11066265
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8575239
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-7750846
CY2024Q1 anvs Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1224000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3875000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
364765
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1066947
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-3354028
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5027044
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1596512
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-5020412
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-1750884
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
28323530
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7386
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1542338
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9737181
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
20136073
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8571191
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1571493
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9537122
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
20742635
us-gaap Profit Loss
ProfitLoss
-6087359
us-gaap Profit Loss
ProfitLoss
-19274303
us-gaap Share Based Compensation
ShareBasedCompensation
1961277
us-gaap Share Based Compensation
ShareBasedCompensation
3113831
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-10761000
anvs Non Cash Financing Costs From Issuance Of Shares
NonCashFinancingCostsFromIssuanceOfShares
1296060
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3404856
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-552521
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2101820
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2788377
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2323591
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2836313
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10407937
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21232641
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8110984
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8571191
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
540000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8386
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8650984
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8579577
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1756953
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12653064
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5754720
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28377693
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3997767
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15724629
anvs Non Cash Transaction Value Of Consideration Warrant Exercises
NonCashTransactionValueOfConsiderationWarrantExercises
684000
anvs Cash Paid For Financing Costs During Period
CashPaidForFinancingCostsDuringPeriod
50000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4000000.0
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116300000
us-gaap Net Income Loss
NetIncomeLoss
-6100000
us-gaap Net Income Loss
NetIncomeLoss
-19300000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15600000
us-gaap Operating Income Loss
OperatingIncomeLoss
-19700000
us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a) Basis of Presentation of Interim Unaudited Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying interim financial statements of Annovis Bio, Inc. should be read in conjunction with the audited financial statements and notes thereto included in the Company’s 2023 Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 29, 2024. The interim financial statements included herein are unaudited. In the opinion of Management, these statements include all adjustments, consisting of normal, recurring adjustments, necessary for a fair presentation of the financial position of Annovis at June 30, 2024, its results of operations for the three and six months ended June 30, 2024 and 2023 and its cash flows for the six months ended June 30, 2024 and 2023. These interim results of operations are not necessarily indicative of the results to be expected for a full year or any future period. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and the rules and regulations of the SEC. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations relating to interim financial statements.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b) Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires Management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant items subject to such estimates and assumptions include the accounting and fair value of equity instruments, common stock warrant liabilities, derivative liabilities, as well as accounting for research and development contracts, including clinical trial accruals. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.</p>
CY2024Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
us-gaap Derivatives Embedded Derivatives
DerivativesEmbeddedDerivatives
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(f) Derivative Liability</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require separate accounting from the underlying agreement under ASC 815 – <i style="font-style:italic;">Derivatives and Hedging</i><span style="white-space:pre-wrap;">. An embedded derivative that requires separation is accounted for as a separate liability or asset from the host agreement. The separated embedded derivative is accounted for at fair market value, with changes in fair value recognized in the statements of operations within the other financing costs line item. The Company determined that certain features under the ELOC Purchase Agreement (See Note 7 — Stockholders’ (Deficit) Equity) collectively qualified as an embedded derivative. The derivative was accounted for separately from the underlying ELOC Purchase Agreement and is accounted for at fair value.</span></p>
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q2 anvs Prepaid Research And Development Expense Current
PrepaidResearchAndDevelopmentExpenseCurrent
728241
CY2023Q4 anvs Prepaid Research And Development Expense Current
PrepaidResearchAndDevelopmentExpenseCurrent
4391219
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
202848
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
23455
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
110104
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
18074
CY2024Q2 us-gaap Security Deposit
SecurityDeposit
7495
CY2023Q4 us-gaap Security Deposit
SecurityDeposit
20796
CY2024Q2 anvs Prepaid Expense Security Deposits And Other Assets Current
PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
1048688
CY2023Q4 anvs Prepaid Expense Security Deposits And Other Assets Current
PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
4453544
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
387435
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
96848
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
275247
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2889425
CY2024Q2 anvs Accrued Liabilities And Interest And Employee Related Liabilities Current
AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
662682
CY2023Q4 anvs Accrued Liabilities And Interest And Employee Related Liabilities Current
AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
2986273
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
24238
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
17712
us-gaap Operating Lease Expense
OperatingLeaseExpense
58113
us-gaap Operating Lease Expense
OperatingLeaseExpense
35273
CY2024Q2 anvs Number Of Classes Of Stock Designated
NumberOfClassesOfStockDesignated
2
CY2024Q2 anvs Common Stock And Preferred Stock Shares Authorized
CommonStockAndPreferredStockSharesAuthorized
72000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2024Q2 anvs Number Of Votes For Each Share Of Common Stock
NumberOfVotesForEachShareOfCommonStock
1
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1596512
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1571493
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1961277
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3113831
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-5020412
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9537122
us-gaap Net Income Loss
NetIncomeLoss
-6087359
us-gaap Net Income Loss
NetIncomeLoss
-19274303
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11307759
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8951309
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10966412
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8575239
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.25
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-5020412
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9537122
us-gaap Net Income Loss
NetIncomeLoss
-6087359
us-gaap Net Income Loss
NetIncomeLoss
-19274303
us-gaap Dilutive Securities
DilutiveSecurities
-10761000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5020412
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9537122
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-16848359
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-19274303
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11307759
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8951309
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10966412
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8575239
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
99853
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11307759
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8951309
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11066265
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8575239
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.52
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.25
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q2 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2023Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0

Files In Submission

Name View Source Status
0001558370-24-012227-index-headers.html Edgar Link pending
0001558370-24-012227-index.html Edgar Link pending
0001558370-24-012227.txt Edgar Link pending
0001558370-24-012227-xbrl.zip Edgar Link pending
anvs-20240630.xsd Edgar Link pending
anvs-20240630x10q.htm Edgar Link pending
anvs-20240630xex31d1.htm Edgar Link pending
anvs-20240630xex32d1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
anvs-20240630_cal.xml Edgar Link unprocessable
anvs-20240630_def.xml Edgar Link unprocessable
anvs-20240630_lab.xml Edgar Link unprocessable
anvs-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
anvs-20240630x10q_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending